| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
BRD4 (BET bromodomain protein 4), TAF1, and TAF1L. UMB-32 binds to BRD4 with a Kd of 550 nM and an IC50 of 637 nM. It also binds to TAF1 (Kd = 560 nM) and TAF1L (Kd = 1.3 μM). BRD4 is a member of the BET family of bromodomain-containing proteins that recognize acetylated lysine residues on histones and play a critical role in transcriptional regulation.
|
|---|---|
| ln Vitro |
In vitro, UMB-32 demonstrates potent and selective inhibition of BRD4 with a Kd of 550 nM and an IC50 of 637 nM. It also binds to TAF1 (Kd = 560 nM) and TAF1L (Kd = 1.3 μM). The compound's activity against multiple bromodomain-containing proteins makes it a useful tool for studying the roles of these proteins in transcriptional regulation.
|
| ln Vivo |
In vivo, UMB-32 has been evaluated in preclinical models to assess its effects on BRD4-dependent transcription and tumor growth. As a BRD4 inhibitor, the compound has potential applications in cancer research, given the role of BRD4 in the expression of oncogenes such as MYC. Its selectivity profile and cellular activity support its use as a chemical probe for studying BET bromodomain function.
|
| Enzyme Assay |
Cell-free binding assays for UMB-32 use purified recombinant BRD4 bromodomain proteins. The compound is incubated with the protein and a fluorescently labeled acetylated histone peptide at varying concentrations (0.01-10000 nM) for 60-120 minutes at room temperature. Binding affinity is measured by fluorescence polarization or AlphaScreen. Kd values are calculated from binding curves. Selectivity profiling is performed against other BET family members (BRD2, BRD3, BRDT) and other bromodomain-containing proteins (e.g., TAF1).
|
| Cell Assay |
Cellular assays for UMB-32 are performed using cancer cell lines (e.g., multiple myeloma, leukemia, or breast cancer cells) that are sensitive to BRD4 inhibition. Cells are seeded in 96-well plates and treated with UMB-32 at concentrations ranging from 0.01-100 μM for 24-72 hours. Cell viability is measured using MTT, CCK-8, or CellTiter-Glo assays. BRD4 target engagement is assessed by measuring the displacement of BRD4 from chromatin using immunofluorescence or ChIP-qPCR. Downstream effects on MYC expression and other BRD4 target genes are measured by qPCR or Western blot analysis. Apoptosis is quantified using Annexin V/PI staining or caspase-3/7 activity assays.
|
| Animal Protocol |
In vivo efficacy studies are conducted in immunodeficient mice bearing subcutaneous xenografts of cancer cell lines sensitive to BRD4 inhibition. UMB-32 is administered via oral gavage or intraperitoneal injection at doses typically ranging from 10-100 mg/kg. Tumor volume is measured every 2-3 days using calipers. At study termination, tumors are excised and processed for immunohistochemistry or Western blot analysis to assess BRD4 target engagement and pharmacodynamic markers (e.g., MYC expression, apoptosis markers). Pharmacodynamic studies involve collecting tumors at various time points post-dose to measure target engagement.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of UMB-32 are consistent with small molecule bromodomain inhibitors. The compound is expected to have reasonable oral bioavailability and sufficient plasma exposure for in vivo efficacy studies. Detailed PK parameters (Cmax, Tmax, AUC, t1/2, clearance, volume of distribution) are determined in preclinical species. Metabolic stability and protein binding are assessed using standard in vitro assays.
|
| Toxicity/Toxicokinetics |
Toxicological data for UMB-32 are limited to preclinical research studies. As a BRD4 inhibitor, potential toxicities may include effects on normal tissues that depend on BRD4 for transcriptional regulation, such as the gastrointestinal tract, bone marrow, and immune system. Standard toxicology studies would be required for clinical development. At research-grade doses, the compound is handled with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
UMB-32 is a research compound for studying BET bromodomain biology and validating BRD4 as a therapeutic target in cancer and other diseases. It is not an approved drug and has not entered clinical trials. The compound is available from chemical suppliers for research purposes only. Its activity against BRD4, TAF1, and TAF1L makes it a valuable tool for dissecting the roles of bromodomain-containing proteins in transcriptional regulation and disease. The compound should be stored at -20°C and handled according to standard laboratory safety protocols.
|
| Molecular Formula |
C21H23N5O
|
|---|---|
| Molecular Weight |
361.44
|
| Exact Mass |
361.19
|
| CAS # |
1635437-39-6
|
| PubChem CID |
86208116
|
| Appearance |
Light yellow to brown solid
|
| Density |
1.2±0.1 g/cm3
|
| Index of Refraction |
1.644
|
| LogP |
3.48
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
501
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C12=NC(C3=CC=C(C4=C(C)ON=C4C)C=C3)=C(NC(C)(C)C)N1C=CN=C2
|
| InChi Key |
YXPVTKHEWGXKEY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H23N5O/c1-13-18(14(2)27-25-13)15-6-8-16(9-7-15)19-20(24-21(3,4)5)26-11-10-22-12-17(26)23-19/h6-12,24H,1-5H3
|
| Chemical Name |
N-tert-butyl-2-[4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]imidazo[1,2-a]pyrazin-3-amine
|
| Synonyms |
UMB32; UMB 32; UMB-32
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~276.7 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.92 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7667 mL | 13.8336 mL | 27.6671 mL | |
| 5 mM | 0.5533 mL | 2.7667 mL | 5.5334 mL | |
| 10 mM | 0.2767 mL | 1.3834 mL | 2.7667 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
